Odapipam (INNTooltip International Nonproprietary Name; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.

It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17nM) over the dopamine D2 receptor (Ki = 942nM). Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported. In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5nM; 26-fold lower than for the D1 receptor).

The drug was first described in the scientific literature by 1988.

See also